CHARLES E. BECKER, M.D.; ROB R. MACGREGOR, M.D.; KEITH S. WALKER, M.D.; JAMES H. JANDL, M.D.
Iron-dextran has been commercially available in the United States since 1957. Despite widespread use, untoward side effects have been uncommon, most often involving local discomfort or staining of the skin at the injection site. Less often there have been generalized reactions, usually of an allergic nature and sometimes progressing to symptoms of serum sickness, including adenopathy, fever, and arthralgias. Personal communication with the manufacturer has revealed that only one report of a fatal reaction, possibly anaphylactic, has been published. The manufacturers have been directly informed, however, of two other deaths in which there was a possible relationship between administration of
CHARLES E. BECKER, ROB R. MACGREGOR, KEITH S. WALKER, JAMES H. JANDL. Fatal Anaphylaxis After Intramuscular Iron-Dextran. Ann Intern Med. 1966;65:745–748. doi: 10.7326/0003-4819-65-4-745
Download citation file:
Published: Ann Intern Med. 1966;65(4):745-748.
Education and Training, Rheumatology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use